Skip Navigation

Annals of Oncology 2007 18(11):1904-1906; doi:10.1093/annonc/mdm487
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Aksoy, S.
Right arrow Articles by Altundag, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Aksoy, S.
Right arrow Articles by Altundag, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2007 European Society for Medical Oncology

letters to the editor

Demographic, clinical, and pathological characteristics of Turkish triple-negative breast cancer patients: single center experience

The first 10% of the full text of this article appears below.

Triple-negative breast cancers are frequently defined as a single group identifiable using routine clinical tests. They are negative for estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2), the so-called ‘triple-negative’ breast cancers. This term originated from hierarchical clustering analysis of gene expression microarray studies [1, 2]. One of the five subtypes of breast cancer identified by these analyses characteristically expressed very low levels of ER and related genes and did not have HER2 overexpression, the triple-negative phenotype. This subtype . . . [Full Text of this Article]

S. Aksoy, O. Dizdar, H. Harputluoglu and K. Altundag*

Department of Medical Oncology, Hacettepe University Institute of Oncology, Ankara, Turkey

* (E-mail: altundag66@yahoo.com)


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?